Global Non-Invasive Cancer Diagnostics Technologies and Markets to 2022

Dublin, Sept. 06, 2017 -- The "Noninvasive Cancer Diagnostics: Technologies and Global Markets" report has been added to Research and Markets' offering.

The global market for non-invasive cancer diagnostics was valued at $107.4 billion in 2016

This market is estimated to grow from nearly $114.6 billion in 2017 to $159.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.

The aim of this report is to initially conduct a review of the non-invasive cancer diagnostics products currently available; assess the market potential by clinical application; examine statistics on the incidence and mortality of cancer; review the issues facing the use of non-invasive cancer diagnostics; and review some of the latest developments into new and innovative non-invasive cancer diagnostic products, their technologies, and their intended clinical applications.

Key objectives are to conduct and provide an analysis of the market value, growth rates, market shares, and market development, as well as examine the market dynamics and market factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufactures in local markets. The emphasis of this report is to provide the reader with:

A detailed analysis of the revenues and forecasts for the global non-invasive cancer diagnostics market with a further, more detailed analysis and forecast of the revenues for the global market subdivided by major market sub-segments by geographic region and finally by selected country.

Key Highlights:

• Diagnostic imaging technologies, the leading segment of this market, will grow from $43.6 billion in 2017 to $58.5 billion by 2022 with a CAGR of 6.1%.
• The market for advanced non-invasive approaches will grow from $40.5 billion in 2017 to $57.9 billion by 2022 with a CAGR of 7.4%.
  

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: Summary And Highlights

Chapter 3: Market And Technology Review: Diagnostic Imaging

Chapter 4: Market And Technology Review: Advanced Non-invasive Cancer

Chapter 5: Market And Technology Review: Conventional Non-invasive Cancer

Chapter 6: Incidence, Prevalence And Mortality Statistics For Cancer: A Global

Chapter 7: Non-invasive Cancer Diagnostics Market By Cancer Type

Chapter 8: Market Analysis By Technology, End User And Market Share

Chapter 9: Technological Advances, Trends And Opportunities

Chapter 10: Regulatory And Legislative Requirements

Chapter 11: Patent Review Of Key Technologies

Chapter 12: Company Profiles

Companies Mentioned

• 20/20 Gene Systems
• Abbott Laboratories
• Andor Technology Ltd. (Oxford Instruments PLC)
• Asuragen Inc.
• Biodesix Inc.
• Biomerieux, S.A.
• Biotheranostics Inc.
• Boreal Genomics
• Cancer Genetics Inc.
• Cepheid Inc.
• Corp.
• Exiqon A/S
• Exosome Diagnostics Inc.
• General Electric Co.
• Genomic Health
• Hologic Inc.
• Ikonisys Inc.
• Illumina Inc.
• Insight Genetics Inc.
• Integragen S.A.
• Mindray
• Myriad Genetics Inc.
• Philips Healthcare Co.
• Qiagen N.V.
• Quantumdx
• Quest Diagnostics
• Roche Molecular Systems Inc.
• Siemens
• Sonosite Inc. (Fujifilm)
• Thermo Fisher Scientific Inc
• Toshiba Corp.
• Trovagene
• Verisante Technology Inc.
• Volcano Corp. (Philips Medical)

For more information about this report visit https://www.researchandmarkets.com/research/5tvt66/noninvasive

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Diagnostics